Hyaluronic acid (HA) is a repeating disaccharide polymer having various biological activities depending on size: high molecular weight HA performs structural functions, whereas low molecular weight HA induces systemic cytokine-like effects. HYC750 is a Good Manufacturing Practices (GMP)-generated HA with an average molecular weight of 750 kDA that is currently in development as a hematopoietic stem cell mobilizer. Given the potential for proinflammatory activities of various low molecular weight HA fragments we sought to determine whether HYC750 may possess properties detrimental to clinical use. Dose-dependent administration of HYC750 to bone marrow stromal cells, the monocytic cell line RAW, and differentiated THP-1 cells did not result in alteration of proliferation or viability. Treatment of said cells with HYC750 did not elicit production of TNF-alpha as assessed by the L929 assay. In contrast, LPS treatment induced a dose dependent cytokine response. These data, combined with dose escalation studies in BALB/c mice without induction of inflammatory reactions or adverse effects suggested HYC750 does not cause biological changes that are conventionally seen with low molecular weight HA administration. In order to quantify hematopoietic stem cell mobilization activity, 240 ug/mouse of HYC750 was administered intraperitoneally for 5 consecutive days and subsequently marrow, spleen and blood samples were collected after sacrifice on day 6. A profound increase in the number of stem cells released into the periphery by HYC750 treatment was determined by forward and side scatter FACS profiles. When compared to G-CSF mobilization, more than a 3-fold increase in stem cell antigen (Sca-1) and c-kit positive cells was observed in animals treated with HYC750, and this treatment was not associated with any decrease in marrow cellularity or local macrophage activation. These data suggest HYC750 is a novel mobilizing agent that does not elicit inflammatory responses. Recently, HYC750 received approval to be used in a Phase I, openlabel, single-ascending-dose, safety study in healthy male volunteers, by the European Competent Authority in Seville, Spain. Banked, unrelated umbilical cord blood units (CBU) provide an option for transplantation in patients where matched adult donors are unavailable. Current methods for selecting a suitable CBU for transplantation include examining the human leukocyte antigen (HLA) matching, total nucleated cell (TNC) count, and viable CD34 counts on the unit prior to cryopreservation. However, 20% of patients experience primary graft failure following UCB transplantation (UCBT), suggesting a rapid assay to assess potency on a thawed CBU prior to the release from the cord blood bank is needed. Preliminary clinical studies demonstrated that neutrophil and platelet engraftment as well as overall survival can be predicted with post-thaw colony forming units (CFU). The usefulness of post-thaw CFU as a potency assay is limited both by time (14 days) and variability. However, CFUs in fresh cord blood are highly correlated with the number of cells expressing the enzyme aldehyde dehydrogenase (ALDH br cells), which is enriched in hematopoietic stem cells. Therefore, an ALDH br assay for segments attached to CBUs was developed to measure potency for UCBT. Retrospective studies of transplanted CBUs indicated that engraftment success could be accurately predicted by the number of ALDH br cells infused per kilogram. In order to facilitate prospective studies, the segment assay was modified to allow HLA matching, CFUs and the ALDH br assay to be done from one segment. Blood was withdrawn from a segment and 3 drops of blood were spotted on a FTA card for HLA confirmatory typing. The remaining blood was washed with 5% dextran/albumin to remove the DMSO. Following removal of 100,000 white blood cells for CFUs, the segment was assessed using flow cytometry for ALDH br [AldecountÒ], CD45, 7-AAD, Glycophorin A and CD34. Each cell population was calculated based on the segment TNC. This method reproducibly assays ALDH br cells (85% CD34/45 positive) from a single segment in less than 4 hr while allowing testing of routine parameters of the CBU (HLA matching, TNC, viable CD34). Furthermore, the assay produces reliable results when performed at different laboratories (Duke vs. MD Anderson) and on different cytometers (Accuri C6 vs. BD Bioscience Facscalibur). Therefore, this method will be suitable for further studies on the predictive value of the ALDH br assay to measure cord blood potency as an indicator of its ability to confer neutrophil and platelet engraftment and overall survival after UCBT.
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CREATION OF A SEGMENT-BASED ALDEHYDE DEHYDROGENASE ASSAY AS A BIOMARKER FOR UMBILICAL CORD BLOOD POTENCY
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THE BIOLOGY AND MEASUREMENT OF HEMATOPOIETIC STEM CELL POTENCY Rich, I.N., Hall, K., Harper, H. HemoGenix, Inc, Colorado Springs, CO Potency is defined as a quantitative measure of biological activity based on a product's intended use. There are several reasons why potency is important. It ensures manufacturing consistency and stability. It allows prediction and/or assurance for the product's performance. It allows evaluation and correlation with the clinical dose. Most important, it avoids product failure and/or toxicity due to improper potency. It follows that potency is a predictor; it cannot be used after the fact as a measure of outcome. For umbilical cord blood (UCB) transplantation, none of the parameters presently used to assess a UCB unit (total nucleated cell (TNC) count, viability, CD34 or colony count from the CFU assay) can be considered potency assays because they do not comply with the definition of potency and stem cell potency, in particular. The intended use is engraftment of the hematopoietic system. For engraftment to occur, the transplanted stem cells have to demonstrate their capability to proliferate. This capability is a measure of stem cell ''quality''. The hematopoietic stem cell compartment is not comprised of a single stem cell population, but a continuum of stem cells with different degrees of self-renewal capacity and proliferation potential (PP). These in turn, will define long-and short-term engraftment potential. The potency assay must therefore measure PP in order for it to predict engraftment potential. A UCB stem cell assay has been developed that measures the PP of two stem cell populations simultaneously, one primitive (HPP-SP), the other mature (CFC-GEMM). A cell dose response for both populations is then compared to a UCB reference standard preparation (a requirement to measure potency). Proliferation status (stem cell quality) and potential are measured by their correlation with the intracellular ATP concentration using a luciferin/luciferase luminescence reporter to produce light that is measured in a plate luminometer. The resulting linear regression slope of the dose response is a direct measure of stem cell PP and therefore potency. Stem cell quality and potency together then provide the acceptance criteria for the UCB unit to be released for transplantation. In a single assay, that can be easily validated, all three parameters, potency, quality and release can be determined simultaneously. Without previous knowledge of hematopoietic stem cell biology, the requirements for a potency assay could not have been met.
BONE MARROW TRANSPLANT INDUCES PULMONARY VASCULAR RE-MODELING IN MICE
Quesenberry, P.J., Del Tatto, M., Dooner, M., Pereira, M., Aliotta, J.M. Rhode Island Hospital, Providence, RI Pulmonary complications are common in bone marrow transplant (BMT) recipients and often of an infectious etiology or attributed to intensive conditioning regimens. Cases of pulmonary arterial hypertension have been described in the setting of autologous BMT but are believed to be the result of acquired infections or previously-administered chemotherapy. Whether transplanted marrow cells themselves are toxic to the recipient's lungs is unknown.
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